Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Recurrence 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

fludarabine phosphate 4Cyclophosphamide 4Rituximab 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Filgrastim 3Etoposide 3Cyclosporine 3venetoclax 2Whole-Body Irradiation 2Ifosfamide 2Cord Blood Stem Cell Transplantation 2Carboplatin 2veltuzumab 1pirtobrutinib 1pevonedistat 1ocaratuzumab 1iratumumab 1fludarabine 1etoposide phosphate 1aldesleukin 1Vincristine 1Tacrolimus 1Sirolimus 1Psychiatric Rehabilitation 1Prednisone 1Microarray Analysis 1Methotrexate 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Dendritic Cell Sarcoma, Interdigitating × iratumumab × Clear all
NCT00059995 2013-05-30

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
DermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡